spacer
home > ict > spring 2018 > improving success rates
PUBLICATIONS
International Clinical Trials

Improving Success Rates

Innovative methodologies are paving the way to a better outlook for Alzheimer’s clinical trials. Improvements in understanding of pathophysiological mechanisms, innovative clinical trial design, and better operational oversight are addressing well-documented research challenges associated with this complex, multifaceted disease.

Daunting failure rates – reaching 99.6% – have historically plagued advancement of new treatments and potential cures for the 28-37 million people impacted (1,2). However, new insights are helping investigators address a continuing source of problematic research: patient recruitment.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Michael F Murphy’s professional career has spanned 25 years and his positions within the pharma industry emphasise the integration of medical and scientific acumen with operational excellence. He is board-certified in psychiatry and has a doctorate in pharmacology, with training at Tulane University, Stanford University, and the Mt Sinai School of Medicine, US. Michael worked with Dr Cutler in articulating this vision for Worldwide Clinical Trials when the company was established as a global CRO in 1995. His supervisory responsibilities as Chief Medical and Scientific Officer at Worldwide are international in scope.
spacer
Dr Michael F Murphy
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

HATRIC-based identification of receptors for orphan ligands (small molecules)

HATRIC-LRC (Ligand Receptor Capture) enables now the identification of small molecule targets on the surface of living cells! Even primary cells!
More info >>

White Papers

Choosing the Right CMO for HPAPI Manufacturing

AMRI

Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
More info >>

 
Industry Events

SMI Immuno-Oncology Conference

25-27 September 2018, Copthorne Tara Hotel, London, UK

Immuno-Oncology is a fast-paced field with massive potential to deliver successful and durable cancer therapies, and SMi's Immuno-Oncology Conference will focus on a few key areas of the field with a representation of the whole industry under each area. These areas will be drawn together to look towards the future of Immuno-oncology and how the field can progress.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement